GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CCX140-B

Company
Amgen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01028963

    A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Amgen 159 participants Est. completion 2010-11 28 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01440257

    A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

    Not yet reported Amgen 20 participants Est. completion 2013-09 1 site Stand-alone
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Completed NCT NCT01447147

    A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

    Not yet reported Amgen 332 participants Est. completion 2014-12 83 sites Stand-alone
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Completed NCT NCT03536754

    A Study of CCX140-B in Subjects With FSGS

    Not yet reported Amgen 46 participants Est. completion 2020-02-19 37 sites Stand-alone
    Other conditions: FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
    View official trial listing →
  • Terminated NCT NCT03703908

    A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

    Not yet reported Amgen 5 participants Est. completion 2020-06-24 5 sites Stand-alone
    Other conditions: Focal Segmental Glomerulosclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.